Recalcitrant chronic urticaria treated with dupilumab: Report of two instances refractory to H1‐antihistamines, omalizumab and cyclosporine and brief literature review-Reference-Cited by-同舟云学术

Recalcitrant chronic urticaria treated with dupilumab: Report of two instances refractory to H1‐antihistamines, omalizumab and cyclosporine and brief literature review

Published:2021-02-02 Issue:2 Volume:34 Page:
ISSN:1396-0296
Container-title:Dermatologic Therapy
language:en
Short-container-title:Dermatologic Therapy

Author:

Errichetti Enzo¹^ORCID,Stinco Giuseppe¹

Affiliation:

1. Institute of Dermatology “Santa Maria della Misericordia” University Hospital Udine Italy

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dth.14821

Reference9 articles.

1. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria

2. UpToDate.Chronic spontaneous urticaria: treatment of refractory symptoms.https://www.uptodate.com/contents/chronic-spontaneous-urticaria-treatment-of-refractory-symptoms. Accessed November 3 2020.

3. Dupilumab use in dermatologic conditions beyond atopic dermatitis – a systematic review

4. Dupilumab as a novel therapy for difficult to treat chronic spontaneous urticaria

5. Severe chronic spontaneous urticaria in children – treatment options according to the guidelines and beyond – a 10 years review

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials;Journal of Allergy and Clinical Immunology;2024-07

2. Omalizumab-induced paradoxical urticaria responsive to dupilumab;Annales de Dermatologie et de Vénéréologie;2023-12

3. Treatment of refractory solar urticaria: could dupilumab fill the current gap?;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2023-05-08

4. Dupilumab in Inflammatory Skin Diseases: A Systematic Review;Biomolecules;2023-03-31

5. Dupilumab: Advances in the off‐label usage ofIL4/IL13antagonist in dermatoses;Dermatologic Therapy;2022-10-20